Garcia Mariana B, Jha Amit K, Healy Kevin E, Wildsoet Christine F
Vision Science Graduate Group, University of California-Berkeley, Berkeley, California, United States.
Department of Bioengineering, University of California-Berkeley, Berkeley, California, United States 3Department of Materials Science and Engineering, University of California-Berkeley, Berkeley, California, United States.
Invest Ophthalmol Vis Sci. 2017 Mar 1;58(3):1875-1886. doi: 10.1167/iovs.16-20694.
To investigate the biocompatibility of an injectable hydrogel and its ability to control myopia progression in guinea pigs.
The study used a hydrogel synthesized from acrylated hyaluronic acid with a conjugated cell-binding peptide and enzymatically degradable crosslinker. Seven-day-old guinea pigs were first form deprived (FD) with diffusers for 1 week. One group was kept as an FD-only control; two groups received a sub-Tenon's capsule injection of either hydrogel or buffer (sham surgery) at the posterior pole of the eye. Form deprivation treatments were then continued for 3 additional weeks. Treatment effects were evaluated in terms of ocular axial length and refractive error. Safety was evaluated via intraocular pressure (IOP), visual acuity, flash electroretinograms (ERG), and histology.
Both hydrogel and sham surgery groups showed significantly reduced axial elongation and myopia progression compared to the FD-only group. For axial lengths, net changes in interocular difference (treated minus control) were 0.04 ± 0.06, 0.02 ± 0.09, and 0.24 ± 0.08 mm for hydrogel, sham, and FD-only groups, respectively (P = 0.0006). Intraocular pressures, visual acuities, and ERGs of treated eyes were not significantly different from contralateral controls. Extensive cell migration into the implants was evident. Both surgery groups showed noticeable Tenon's capsule thickening.
Sub-Tenon's capsule injections of both hydrogel and buffer inhibited myopia progression, with no adverse effects on ocular health. The latter unexpected effect warrants further investigation as a potential novel myopia control therapy. That the hydrogel implant supported significant cell infiltration offers further proof of its biocompatibility, with potential application as a tool for drug and cell delivery.
研究一种可注射水凝胶的生物相容性及其控制豚鼠近视进展的能力。
本研究使用了一种由丙烯酸化透明质酸与共轭细胞结合肽和酶促可降解交联剂合成的水凝胶。7日龄豚鼠首先用扩散器进行1周的形觉剥夺（FD）。一组作为仅FD对照组；两组在眼球后极进行Tenon囊下注射水凝胶或缓冲液（假手术）。然后继续进行3周的形觉剥夺治疗。根据眼轴长度和屈光不正评估治疗效果。通过眼压（IOP）、视力、闪光视网膜电图（ERG）和组织学评估安全性。
与仅FD组相比，水凝胶组和假手术组的眼轴伸长和近视进展均显著降低。对于眼轴长度，水凝胶组、假手术组和仅FD组的眼间差异净变化（治疗组减去对照组）分别为0.04±0.06、0.02±0.09和0.24±0.08mm（P = 0.0006）。治疗眼的眼压、视力和ERG与对侧对照组无显著差异。明显有大量细胞迁移到植入物中。两个手术组均显示Tenon囊明显增厚。
Tenon囊下注射水凝胶和缓冲液均能抑制近视进展，且对眼部健康无不良影响。后一种意外效果作为一种潜在的新型近视控制疗法值得进一步研究。水凝胶植入物支持显著的细胞浸润，进一步证明了其生物相容性，具有作为药物和细胞递送工具的潜在应用价值。
Zotero 插件
